Research Topics
Genomes and GenesSpecies | David GrimwadeSummaryAffiliation: King's College London Country: UK Publications
| Collaborators
|
Detail Information
Publications
Diagnostic and prognostic value of cytogenetics in acute myeloid leukemiaDavid Grimwade
Cancer Genetics Laboratory, Department of Medical and Molecular Genetics, Guy s Hospital, King s College London School of Medicine, 8th Floor, Guy s Tower, London SE1 9RT, UK
Hematol Oncol Clin North Am 25:1135-61, vii. 2011..Cytogenetics has been widely adopted to provide the framework for development of risk-stratified treatment approaches to patient management...- The changing paradigm of prognostic factors in acute myeloid leukaemiaDavid Grimwade
Department of Medical and Molecular Genetics, King s College London School of Medicine, UK
Best Pract Res Clin Haematol 25:419-25. 2012.... - Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapyDavid Grimwade
Dept of Medical and Molecular Genetics, King s College London School of Medicine, 8th Floor, Tower Wing, Guy s Hospital, London SE1 9RT, United Kingdom
J Clin Oncol 27:3650-8. 2009.... - Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trialsDavid Grimwade
Department of Medical and Molecular Genetics, King s College London School of Medicine and Department of Haematology, Guy s and St Thomas NHS Foundation Trust, London, United Kingdom
Blood 116:354-65. 2010..This study is registered at http://www.isrctn.org as ISRCTN55678797 and ISRCTN17161961... - Assessment of minimal residual disease in acute myeloid leukemiaDavid Grimwade
Department of Medical and Molecular Genetics, King s College London School of Medicine, Guy s and St Thomas NHS Foundation Trust, London, UK
Curr Opin Oncol 22:656-63. 2010..We review recent studies highlighting the potential for novel and standardized assays to provide independent prognostic information and develop more personalized treatment approaches... - Acute promyelocytic leukemia: a paradigm for differentiation therapyDavid Grimwade
Department of Medical and Molecular Genetics, King s College London School of Medicine, London, UK
Cancer Treat Res 145:219-35. 2010..This represents an exciting new phase in the treatment of acute leukemia, highlighting the potential of molecularly targeted and MRD-directed therapies to achieve an individualized approach to patient management... 
Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemiaAshley N Mays
Department of Medical and Molecular Genetics, King s College London School of Medicine, London, United Kingdom
Blood 115:326-30. 2010....
Real-time quantitative RT-PCR to detect fusion gene transcripts associated with AMLRajinder Flora
Guy's, King's, and St Thomas' School of Medicine, London, UK
Methods Mol Med 91:151-73. 2004- RARalpha-PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t(11;17) acute promyelocytic leukemiaFabien Guidez
Department of Medical and Molecular Genetics, King s College London, Guy s Hospital, London SE1 9RT, United Kingdom
Proc Natl Acad Sci U S A 104:18694-9. 2007.... - The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the diseaseAnita R Mistry
Division of Medical and Molecular Genetics, Guy's, King's and St Thomas' School of Medicine, London, UK
Blood Rev 17:71-97. 2003.... - Development of real-time quantitative polymerase chain reaction assays to track treatment response in retinoid resistant acute promyelocytic leukemiaJelena V Jovanovic
Cancer Genetics Laboratory, Department of Medical and Molecular Genetics, King s College London School of Medicine London, UK
Front Oncol 1:35. 2011..These data highlight the potential of RT-qPCR detection of MRD to facilitate development of more individualized approaches to the management of rarer molecularly defined subsets of acute leukemia... - Molecular biology of therapy-related leukaemiasMelanie Joannides
Department of Medical and Molecular Genetics, King s College London School of Medicine, Guy s Hospital, London, UK
Clin Transl Oncol 12:8-14. 2010..Although treatment of therapy-related leukaemias represents a considerable challenge due to prior therapy and comorbidities, curative therapy is possible, particularly in those with favourable karyotypic features... - PML nuclear bodies in the pathogenesis of acute promyelocytic leukemia: active players or innocent bystanders?Nicola J M Brown
Department of Medical and Molecular Genetics, King s College London School of Medicine, London, UK
Front Biosci 14:1684-707. 2009.... - The T-lineage-affiliated CD2 gene lies within an open chromatin environment in acute promyelocytic leukemia cellsDavid Grimwade
Division of Medical and Molecular Genetics, Guy s, King s and St Thomas School of Medicine, London SE1 9RT, UK
Cancer Res 62:4730-5. 2002..The demonstration of T-cell-associated chromatin features in primary APL blasts has implications for the origin of APL that may arise in more primitive progenitors than previously considered to be the case... - Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemiaJelena V Jovanovic
Department of Medical and Molecular Genetics, Guy s Hospital, King s College London, UK
Blood 109:4635-40. 2007.... - Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemiaLetizia Foroni
Department of Haematology, Imperial College Academic Health Science Centre, Hammersmith Hospital, Du Cane Rd, London, UK
Br J Haematol 153:179-90. 2011.... - Independent prognostic variables in acute myeloid leukaemiaMatthew L Smith
Department of Haematology, St Bartholomew s Hospital, London, UK
Blood Rev 25:39-51. 2011.... - DNA topoisomerase II in therapy-related acute promyelocytic leukemiaAnita R Mistry
Department of Medical and Molecular Genetics, Guy's, King's, and St. Thomas' School of Medicine, London
N Engl J Med 352:1529-38. 2005..CONCLUSIONS: Drug-induced cleavage of DNA by topoisomerase II mediates the formation of chromosomal translocation breakpoints in mitoxantrone-related APL and in APL that occurs after therapy with other topoisomerase II poisons... - The significance of minimal residual disease in patients with t(15;17)David Grimwade
Division of Medical and Molecular Genetics, Guy's, King's and St Thomas' School of Medicine, Cancer Genetics Laboratory, 8th Floor, Guy's Tower, Guy's Hospital, London SE1 9RT, UK
Best Pract Res Clin Haematol 15:137-58. 2002.... - Molecular markers in acute myeloid leukaemiaAndrea Kühnl
Department of Medical and Molecular Genetics, King s College London School of Medicine, London, UK
Int J Hematol 96:153-63. 2012..Finally, molecular markers are important for the detection of minimal residual disease after initial therapy and during long-term follow-up, which enables a more tailored treatment approach for individual AML patients... - Mutation of the RAD51C gene in a Fanconi anemia-like disorderFiona Vaz
Department of Medical and Molecular Genetics, King s College London School of Medicine, Guy s Hospital, London, UK
Nat Genet 42:406-9. 2010..Thus, biallelic germline mutations in a RAD51 paralog are associated with an FA-like syndrome...